Skip to main content
Clinical Trials/NCT04270799
NCT04270799UnknownNot Applicable

Lung Nodule Imaging Biobank for Radiomics and AI Research

Royal Marsden NHS Foundation Trust5 sites in 1 country1,000 target enrollmentStarted: June 1, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
1,000
Locations
5
Primary Endpoint
Development of an imaging biobank

Study Overview

Brief Summary

This study will collect retrospective CT scan images and clinical data from participants with incidental lung nodules seen in hospitals across London. The investigators will research whether machine learning can be used to predict which participants will develop lung cancer, to improve early diagnosis.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age > 18
  • Baseline CT thorax imaging reported as having pulmonary nodule(s) between 5 and 30mm in the last 10 years.
  • Ground truth known (either scan data showing stability for 2 years (based on diameter) or one year (based on volumetry), complete resolution, or biopsy-proven malignancy.
  • Slice thickness < 2.5mm.

Exclusion Criteria

  • • Absence of at least one technically adequate CT thorax imaging series (defined by visual inspection of presence of imaging data of the thorax in the DICOM record).
  • Slice thickness > 2.5mm.
  • Imaging > 10 years old.
  • Ground truth unknown.

Outcomes

Primary Outcomes

Development of an imaging biobank

Time Frame: 1 year

The primary endpoint will be met if we are able to store baseline CT scans and the minimum clinical data set for 1000 patients.

Secondary Outcomes

  • Discovery of a CT-thorax based radiomics profile to predict cancer risk.(1 year)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (5)

Loading locations...

Similar Trials

Lung Nodule Imaging Biobank for Radiomics... | Clinical Trial